Soterix Medical Inc. (SMI) was formed to develop and deploy innovative medical treatments focused on neuropsychiatric and neurological disorders and rehabilitation. Founded in 2008, SMI is the world leader in clinical trials for non-invasive neuromodulation working with over 250 medical centers in the US and worldwide. SMI has licensed and developed a comprehensive intellectual property portfolio that includes High-Definition transcranial Direct Current Stimulation (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. From the most targeted non-invasive clinical systems to the most portable units, Soterix Medical provides clinicians and patients with unique and adaptable solutions. Ongoing Phase I, II, IIb, and III trials use investigational devices that are regulated/limited by US or Federal law. SMI is proudly based in New York City with international distributors in all major markets.

Engineering Serving Humanity

At Soterix Medical, Engineering Serving Humanity means that we are committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.

Press Releases

Soterix Medical, Inc. announced today that it is seeking physicians and clinical centers across the European Union (EU) to join its tDCS-LTE™ Depression Treatment partnership program. This announcement follows the receipt of CE Mark approval for its tDCS-LTE™ Therapy System for the treatment of Major Depressive Disorder (MDD). As part of this program, Soterix Medical will directly work with medical administrators and physicians in helping them incorporate tDCS-LTE™ into their practice. Soterix Medical will provide specialized education, training, and treatment guidance based on validation of its technology at leading centers worldwide. Structured around regional hubs, the program will also provide physicians access to a patient referral program connecting patients to local physicians. Interested groups in the EU can contact the Soterix Medical immediately at contact@soterixmedical.com.

"The Depression Treatment partnership program will expedite and simplify incorporating our technology into clinical practice,” said Shani San Solo, VP Europe Business, Soterix Medical, “The tDCS-LTE™ Therapy System for Depression is the only transcranial Direct Current Stimulation (tDCS) technology designed for routine clinical use, including clinical-grade hardware, software, and accessories. We intend to directly educate physicians so that they get access to quality technology and are able to re-create successful treatment protocols”.

Dr. Abhishek Datta, Soterix Medical Scientist and CTO explains, “This program continues to be part of Soterix Medical’s mission to provide relief to patients worldwide. The program bridges the gap between tDCS experience at academic research studies and its application in medical practice. Our support of the most comprehensive tDCS clinical trials, allows us to immediately facilitate controlled transition to the practitioners’ offices. Ultimately, clinicians choose Soterix Medical systems for the same reason as academic researchers: because patient safety and treatment efficacy cannot be compromised.”

Soterix Medical’s Partnership program includes support on the entire patient treatment pipeline,
hands-on training and staff certification, and connection to our network of physician researchers. Guidance on integrating tDCS with other treatments such as rTMS and ECT is available.

At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.